Skip to content
ESPT
MARKETS / NASDAQ / Health care / Biotechnology / ELUT
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Elutia Inc. ELUT

7 fiscal years on record · USD · FY2025 reported · SEC filings only
$12.3M
▼ 15.0% YoY
$53.4M
$-46.7M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

We develop proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. Our operations span research and development through the commercial distribution of biologic matrix products used in plastic and reconstructive surgery. on October 1, 2025, we divested one such product family through the sale of substantially all of the assets related to our business of developing, commercializing, manufacturing, selling and marketing our cardiac implantable electronic device (“CIED”) products, EluPro™ and CanGaroo®, to Boston Scientific Corporation (“BSC”) and Cardiac Pacemakers Inc (“CPI”) for an aggregate purchase price of up to $88.0 million in cash. Following the sale of the CIED business, we are focused on advancing our drug-eluting biomatrix (“DEB”) platform.

Written from the business description in Elutia Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 13 March 2026. Every sentence was checked against that document before publication.

Growth

USD 12.3M
Revenue, FY2025 · full 7-year series below
Revenue $M Net income $M
FY2025 · Revenue 12.3 · Net income 53.4
20M40M-20M-40M
201920222025
Compound annual growth
−19.8%
−22.0%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −22.0% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

434 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating -218.9% · Net 434.2%
200%400%-100%-200%-300%
201920222025
ROE

Not applicable: equity was zero or negative in this period, so return on equity has no meaning.

Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Return on capital employedNot applicable: capital employed was zero or negative in this period, so return on capital employed has no meaning.
Gross margin53.7%
Operating margin-218.9%
Net margin434.2%
EBITDAUSD -24.1M

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -46.7
-20M-40M
201920222025
Dividends paid·
Net buybacks·
Share of profit·
Consecutive raises·

Total assetsUSD 62.4M
EquityUSD 27.7M
CashUSD 36.4M
Current ratio2.22×

Equity funds 44% of total assets.

The 7-year record

7 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
ELUT, 7-year financial record
Metric 2025202420232022202120202019
Revenue $B0.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B0.00.00.00.00.00.00.0
Net income $B0.1−0.1−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $0.87−1.86−2.07−2.38−2.38−8.88−18.48
Dividend / sh $◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————
ROE %————−144.6——
Shares out B◌◌◌◌◌◌0.00

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

MCK · COR · CAH · JNJ · HCA · LLY
Provenance

Company facts, as filed

How we verify · 0 failures in 35 reconciliationsAUDITED

Reconciled in 7 of the 7 fiscal years we could check. 24 checks were skipped: the balance sheet is not tagged before 2019. 12 checks were skipped: EPS is not tagged before 2019. 12 checks were skipped: revenue is not tagged before 2019.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2019

Share this section

Download image